Gilead Sciences Inc
NASDAQ: GILD
$90.49
+$0.30 (+0.3%)
Closing Price on November 25, 2024
GILD Articles
The October 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Published:
Last Updated:
Here is a preview of some of the world’s largest players in the health care sector reporting earnings this coming week.
Published:
Last Updated:
The September 28 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Published:
Last Updated:
The September 14 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Published:
Last Updated:
There is one fairly new effort for drug companies to mitigate the threat of generic drugs and for biotech companies to mitigate the threat of biosimilars. They can just launch their own. Several...
Published:
Last Updated:
Jefferies highlights the firm's top growth stocks to buy each week, and recently four top biotech stocks made the cut. They all make good sense now, and all have outstanding upside potential.
Published:
Last Updated:
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The August 31 short interest data have been compared with the previous report, and short interest in...
Published:
Last Updated:
Gilead shares were up handily on Wednesday after the company announced that it had entered into a strategic collaboration with Precision BioSciences.
Published:
Last Updated:
The topic of acceptable costs versus acceptable results is one that may never have a final conclusion in which everyone agrees.
Published:
Last Updated:
The August 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Published:
Last Updated:
The July 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Thursday include Dolby Laboratories, Facebook, Freeport-McMoRan, Gilead, GrubHub and Skechers.
Published:
Last Updated:
Gilead reported its most recent quarterly results after the markets closed on Wednesday. The major biotech posted $1.91 in earnings per share (EPS) and $5.65 billion in revenue, versus with consensus...
Published:
Last Updated:
Gilead is scheduled to release its second-quarter financial results after the markets close on Wednesday, and analyst expectations are low.
Published:
Last Updated:
The July 13 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Published:
Last Updated: